fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

How ivermectin works – and how this plays out in practice

Written by | 20 Apr 2021

Interview and article by Christine Clark. Dr Jackie Stone, who has treated numerous covid-19 patients, explains how ivermectin is used in early stage disease to prevent progression and… read more.

Hypothesis for rare side effect linked to AstraZeneca vaccine

Written by | 19 Apr 2021

A hypothesis has been put forward as to why COVID-19 Vaccine AstraZeneca (ChAdOx1 nCov-19) seems to trigger an abnormal and potentially life-threatening combination of blood clotting and low… read more.

The impact of ivermectin use in Zimbabwe

Written by | 19 Apr 2021

The use of ivermectin for prophylaxis and treatment of covid-19 in Zimbabwe has resulted in a 10-fold reduction in mortality. IMI interviewed Dr Jackie Stone, a family medicine physician in based in Harare, Zimbabwe to find out more.

Cycling study transforms heart health of dialysis patients

Written by | 18 Apr 2021

Cycling at moderate intensity during dialysis could drastically improve the heart health of patients with kidney failure and result in significant savings for the NHS, according to new… read more.

Childhood diet and exercise creates healthier, less anxious adults

Written by | 16 Apr 2021

Exercise and a healthy diet in childhood leads to adults with bigger brains and lower levels of anxiety, according to new UC Riverside research in mice.

EU approves SC version of Tysabri for multiple sclerosis – Biogen

Written by | 14 Apr 2021

Biogen announced that the European Commission (EC) has granted marketing authorization for a subcutaneous (SC) injection of Tysabri (natalizumab) to treat relapsing-remitting multiple sclerosis (MS).

Novel pharmacological strategies to treat alcoholism. Focus on epigenetics

Written by | 11 Apr 2021

Abusive alcohol drinking considerably impacts human health. Alcoholism, better defined as Alcohol Use Disorders (AUD), includes a group of pathological entities related to alcohol-induced damage. Individuals with AUD… read more.

AZD 1222 US phase III trial met primary efficacy endpoint in preventing COVID-19 at interim analysis – AstraZeneca

Written by | 9 Apr 2021

The AstraZeneca US Phase III trial of AZD 1222 demonstrated statistically significant vaccine efficacy of 79% at preventing symptomatic COVID-19 and 100% efficacy at preventing severe disease and… read more.

Community pharmacy input to Vac4covid

Written by | 8 Apr 2021

Interview and article by Christine Clark. Community pharmacies are at the heart of their communities and can contribute to the Vac4covid study by signposting patients to the website,… read more.

How the Vac4covid study will collect data

Written by | 7 Apr 2021

Interview and article by Christine Clark. Gavin Dobson, Clinical Trials Pharmacist at MEMO Research explains the practical details of the Vac4covid study. The Vac4covid study will recruit at… read more.

Studying people’s experience of covid-19 vaccination – Vac4covid

Written by | 6 Apr 2021

Interview and article by Christine Clark. The Vac4covid study has been designed to provide important data about the safety and effectiveness of covid-19 vaccines. IMI interviewed Mr Gavin… read more.

Pfizer-BioNTech announce positive topline results of pivotal COVID-19 vaccine study in adolescents

Written by | 4 Apr 2021

Pfizer Inc. and BioNTech SE announced that, in a Phase III trial in adolescents 12 to 15 years of age with or without prior evidence of SARS-CoV-2 infection,… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.